title: Effect of selective ET(A) receptor blockade on natriuretic peptide gene expression in DOCA-salt hypertension.
abstract: To determine the role of endothelin-1 (ET-1) in the upregulation of atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) observed in deoxycorticosterone acetate (DOCA)-salt hypertension, the selective ET-1 type-A receptor (ET(A)) antagonist ABT-627 was chronically administered to normal controls and hypertensive rats. Chronic ET(A) blockade in DOCA-salt-treated rats prevented the increase in blood pressure and circulating natriuretic protein (NP) levels and partially prevented left ventricular hypertrophy. The changes observed in NP gene expression in the atria were not affected by ABT-627. In the ventricles, ABT-627 reduced NP gene expression. Rats receiving the ET(A) antagonist alone showed reduced left ventricular NP gene expression. ABT-627 did not affect ventricular collagen III gene expression but enhanced left ventricular alpha-myosin heavy chain expression. These findings suggest that in vivo, ventricular but not atrial NP production is regulated by ET-1. This difference in response between atrial and ventricular NP gene expression to ET(A) receptor blockade is similar to that observed by us after applying angiotensin-converting enzyme inhibitors in other hypertensive models. In general therefore, atrial NP gene expression may not be as sensitive to the endocrine environment as is ventricular NP gene expression.
authors.affiliation: University of Ottawa Heart Institute and the Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada K1Y 4W7.
authors.forename: L G
authors.initials: LG
authors.lastname: Bianciotti
authors.forename: A J
authors.initials: AJ
authors.lastname: De Bold
mesh_terms: D000818:Animals; D000077868:Atrasentan; D009320:Atrial Natriuretic Factor / Q000235:genetics*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003900:Desoxycorticosterone; D065128:Endothelin Receptor Antagonists; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000502:physiology; D006321:Heart / Q000187:drug effects; D006352:Heart Ventricles; D006973:Hypertension / Q000139:chemically induced / Q000235:genetics / Q000503:physiopathology*; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D018995:Myosin Heavy Chains / Q000235:genetics; D020097:Natriuretic Peptide, Brain / Q000235:genetics*; D009929:Organ Size; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A; D012982:Sodium, Dietary; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D065128:Endothelin Receptor Antagonists; D011759:Pyrrolidines; D044022:Receptor, Endothelin A; D012982:Sodium, Dietary; D020097:Natriuretic Peptide, Brain; D003900:Desoxycorticosterone; D009320:Atrial Natriuretic Factor; D018995:Myosin Heavy Chains; D000077868:Atrasentan